Sanofi-Aventis and Lilly in Cialis marketing pact

Sanofi-Aventis has teamed with Eli Lilly in a collaboration to market erectile-dysfunction drug Cialis (tadalafil) to US urologists. 

According to Lilly spokesperson Lee Lang, the campaign hopes to “educate urologists nationwide by providing direct selling support for 2.5 mg and 5 mg doses, as well as for use on an ‘as needed' basis.” Lang explains the decision, noting Sanofi's “strong market position in urology.”
Sanofi-Aventis spokeswoman Noelle Boyd added, “Our sales force has developed trust among urologists over the years.” Sanofi-Aventis markets Uroxatral (alfuzosin HCI), for benign prostatic hyperplasia (BPH), and Taxotere (docetaxel), a chemotherapy indicated for prostate cancer, to urologists.

The partnership follows FDA approval in January for a once-daily use in 2.5 mg and 5 mg doses.  Cialis is also known as the “36 hour pill” or the “weekend pill,” due to its longer duration of action in patients. 

A spokesperson for Lilly told CNNMoney that the collaboration with Sanofi-Aventis began on March 13.  On the consumer side, Cialis was recently ranked second in the Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests, according to a Manhattan Research study. 
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.